ReviewEuropean journal of haematology2019
Clinical implications of molecular markers in acute myeloid leukemia.
Review in European journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 62 citations in OpenAlex.
- Machine Learning to Predict Risk of Relapse Using Cytologic Image Markers in Patients With Acute Myeloid Leukemia Posthematopoietic Cell Transplantation.JCO clinical cancer informatics · 2022Trial
- Molecular, Cytogenetic, and Immunophenotypic Biomarkers in Acute Myeloid Leukemia: Current Evidence and Future Directions-A Narrative Review.Health science reports · 2026Article
- Mitochondrial RNA helicase DDX28 promotes cell cycle and DNA repair programs and shapes an immunosuppressive microenvironment in acute myeloid leukemia.Translational oncology · 2026Article
- A Simple and Fast Protocol to Detect Nucleophosmin 1 (Methods and protocols · 2026Article
- PRC2-Related Epigenetic Age Acceleration in Acute Myeloid Leukemia with DNMT3A and IDH2 Mutations.Advanced biology · 2026Article
- miR-379-5p Inhibited the Proliferation of Acute Myeloid Leukemia Cells Through Negative Regulation ofTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025Article
- Minimal Residual Disease in Acute Lymphoblastic Leukaemia and Its Relationship with Other Prognostic Factors.International journal of hematology-oncology and stem cell research · 2025Article
- SFXN3 is a Prognostic Marker and Promotes the Growth of Acute Myeloid Leukemia.Cell biochemistry and biophysics · 2024Article
- Article
- MICAL1 promotes the proliferation in acute myeloid leukemia and is associated with clinical prognosis and immune infiltration.Discover oncology · 2024Article
- MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia.Clinical epigenetics · 2024Article
- Article
- Downregulation of RCN1 promotes pyroptosis in acute myeloid leukemia cells.Molecular oncology · 2023Article
- Identification of prognostic and driver gene mutations in acute myeloid leukemia by a bioinformatics analysis.Translational cancer research · 2023Article
- Loss of IRF8 inhibits the growth of acute myeloid leukemia cells.Annals of hematology · 2023Article
- Association between Immunophenotypic Parameters and Molecular Alterations in Acute Myeloid Leukemia.Biomedicines · 2023Review
- Chidamide works synergistically with Dasatinib by inducing cell-cycle arrest and apoptosis in acute myeloid leukemia cells.Molecular and cellular biochemistry · 2023Article
- The Relationship between Gene Polymorphisms od the XRCC1 and TP53 with the Gender of Children with Acute Leukemia.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- KLK2 single-nucleotide polymorphism rs198977 is associated with increased susceptibility and hyperleukocytosis in AML.Frontiers in genetics · 2023Article
- Efficacy of bone marrow transplantation in treating acute myeloid leukemia: a systematic review and meta-analysis.American journal of translational research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
The recently updated World Health Organization (WHO) Classification of myeloid neoplasms and leukemia reflects the fact that research in the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has led to remarkable advances in our understanding of the disease. Gene mutations now allow us to explore the enormous diversity among cytogenetically defined subsets of AML, particularly the large subset of cytogenetically normal AML. Despite the progress in unraveling the tumor genome, only a small number of recurrent mutations have been incorporated into risk-stratification schemes and have been proven to be clinically relevant, targetable lesions. We here discuss the utility of molecular markers in AML in prognostication and treatment decision making, specifically highlighting the aberrations included in the current WHO classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.